A detailed history of Hrt Financial LP transactions in Uni Qure N.V. stock. As of the latest transaction made, Hrt Financial LP holds 26,014 shares of QURE stock, worth $451,342. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,014
Holding current value
$451,342
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.78 - $10.12 $98,332 - $263,261
26,014 New
26,014 $128,000
Q1 2024

May 13, 2024

SELL
$4.82 - $6.93 $57,097 - $82,092
-11,846 Reduced 20.83%
45,035 $234,000
Q4 2023

Feb 09, 2024

SELL
$5.63 - $8.27 $871,326 - $1.28 Million
-154,765 Reduced 73.12%
56,881 $385,000
Q3 2023

Nov 13, 2023

BUY
$6.71 - $11.83 $1.42 Million - $2.5 Million
211,646 New
211,646 $1.42 Million
Q4 2022

Feb 10, 2023

BUY
$18.12 - $27.32 $2.3 Million - $3.47 Million
127,108 New
127,108 $2.88 Million
Q2 2022

Aug 12, 2022

BUY
$13.15 - $20.45 $1.18 Million - $1.83 Million
89,684 New
89,684 $1.67 Million
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $278,513 - $411,832
-19,155 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$20.24 - $36.01 $387,697 - $689,771
19,155 New
19,155 $397,000
Q3 2021

Nov 15, 2021

SELL
$26.01 - $38.22 $1.16 Million - $1.7 Million
-44,532 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $1.33 Million - $1.66 Million
44,532 New
44,532 $1.37 Million
Q3 2020

Nov 13, 2020

SELL
$35.98 - $47.66 $380,632 - $504,195
-10,579 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$45.06 - $67.74 $476,689 - $716,621
10,579 New
10,579 $476,000
Q1 2019

May 14, 2019

SELL
$27.39 - $68.41 $274,776 - $686,289
-10,032 Closed
0 $0
Q4 2018

Feb 15, 2019

BUY
$22.8 - $33.93 $228,729 - $340,385
10,032 New
10,032 $289,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.